Merck Receives Breakthrough Therapy Designation from U.S.FDA for KEYTRUDA(R) (pembrolizumab) in Advanced Colorectal Cancer

By: via Benzinga
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.